Saturday, May 27, 2017

Going Up…The Elevator Has Left The Basement

When I last wrote about biOasis, I compared the shares to a designer suit in Filene’s Basement, a store where each week items were...

biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director

Tailwinds' Take: Dr. Day is a well respected thought leader and proven business development executive. The combination of his talents with the pipeline of...

biOasis Closes Upsized Private Placement

Last night, biOasis Technologies announced that they have closed their non-brokered placement. The Company  issued 5,797,795 units (each a "Unit") at a price of CDN$0.70 per...

biOasis Announces Oversubscription of Financing

Tailwinds' Take: This is THE catalyst we have been expecting from biOasis. While it took a long time to get this deal done, I...

biOasis Arranges $3.15-Million Private Placement

Tailwinds' Take: This is the catalyst for which the market has been waiting. With this funding, they will garner "in human" results from a Phase...

biOasis: The Storm Before The Calm?

Shares in biOasis have been under pressure for a while, the stock having drifted down from last year’s high of $2.05 to where it’s...

biOasis: Valuing the Licensing Opportunities (Why biOasis is Cash Flow Positive in 2017)

Every drug maker has encountered serious issues when trying to take their therapies across the blood brain barrier and into the central nervous system....

biOasis Provides AGM Update – Expanding The biOasis Deal Flow Pipeline

January 22, 2017, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier...
video

biOasis: The Enabler Video Series, Part 1

This first in a series of videos, discusses the genesis of biOasis' groundbreaking Transcend platform, its business model, and its pre-clinical success. Tailwinds Research is...

biOasis Investor Presentation

The biOasis Investor Presentation provides valuable insight into the Company’s clinical development and the amazing potential of the Transcend platform. The results of preclinical...

Prolonging Life…biOasis Platform Represents Hope for CNS Diseases

Thursday, I went to a funeral Mass of one of our neighbors.  She had always been in good shape, never overweight, instead on the...
video

biOasis: The Enabler (video)

biOasis, with its Transcend platform, enables medications to cross the Blood Brain Barrier in greater quantities, possibly transforming treatment of Central Nervous System diseases. Tailwinds Research...

biOasis CEO Audio Interview

Hear CEO Rob Hutchison discuss target therapeutic areas of focus for the Company. Tailwinds Research is engaged by biOasis for investor relations services. Please see...

Understanding the biOasis Drug Delivery Platform

True Story: I fell in love with biOasis at a speed dating event. It was, of course, speed dating for investors. Fifteen minutes with a...
video

Three reasons to consider biOasis for your portfolio

biOasis Technologies represents a unique investment opportunity for investors looking for a platform that could change the whole market for CNS drug delivery and,...

biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured...

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address